United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $474.64, for a total value of $1,898,560.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $61,703.20. The trade was a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Up 0.0%

UTHR stock traded up $0.10 during midday trading on Friday, reaching $474.82. 430,075 shares of the company’s stock traded hands, compared to its average volume of 589,955. The company has a 50-day simple moving average of $439.78 and a two-hundred day simple moving average of $355.47. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $485.32. The company has a market cap of $20.44 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.39 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Trading of United Therapeutics

Hedge funds have recently modified their holdings of the company. CWM LLC lifted its holdings in shares of United Therapeutics by 204.3% during the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after buying an additional 3,487 shares in the last quarter. XTX Topco Ltd bought a new position in United Therapeutics during the first quarter worth about $313,000. Allianz Asset Management GmbH increased its position in United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after acquiring an additional 33,254 shares during the period. LPL Financial LLC raised its stake in United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock worth $7,783,000 after purchasing an additional 11,007 shares in the last quarter. Finally, AXQ Capital LP grew its position in shares of United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Cantor Fitzgerald lifted their target price on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. HC Wainwright raised their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Oppenheimer boosted their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research report on Wednesday. Finally, Royal Bank Of Canada raised their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.